Atabecestat (JNJ-54861911)

first patented BACE1 protease inhib. of series

Ph. II/III in Alzheimer’s, discontinued (tox.)

from phenotypic screen and SBDD

J. Med. Chem., Feb. 15, 2021

Shionogi Pharmaceutical, Osaka, JP

9. The Shionogi BACE1 aspartyl protease inhibitor, atabecestat (JNJ-54861911) is an oral, brain-penetrant compound that was advanced into the EARLY Ph. IIb/III clinical trial for treatment of preclinical Alzheimer’s…

become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

Stay up-to-date and save more time with exclusive members-only content
On-board new team members with educational content and case studies

Generate ideas and discussion with easy-to-read slide decks
Generate ideas and discussion with easy-to-read slide decks